149 related articles for article (PubMed ID: 16984132)
21. Folate-targeted chemotherapy.
Leamon CP; Reddy JA
Adv Drug Deliv Rev; 2004 Apr; 56(8):1127-41. PubMed ID: 15094211
[TBL] [Abstract][Full Text] [Related]
22. Folate-mediated tumor cell uptake of quantum dots entrapped in lipid nanoparticles.
Schroeder JE; Shweky I; Shmeeda H; Banin U; Gabizon A
J Control Release; 2007 Dec; 124(1-2):28-34. PubMed ID: 17928088
[TBL] [Abstract][Full Text] [Related]
23. Enhanced tumor detection using a folate receptor-targeted near-infrared fluorochrome conjugate.
Moon WK; Lin Y; O'Loughlin T; Tang Y; Kim DE; Weissleder R; Tung CH
Bioconjug Chem; 2003; 14(3):539-45. PubMed ID: 12757377
[TBL] [Abstract][Full Text] [Related]
24. [New antitumor derivatives of vinblastine].
Bölcskei H; Szántay C; Mák M; Balázs M; Szántay C
Acta Pharm Hung; 1998 Mar; 68(2):87-93. PubMed ID: 9592933
[TBL] [Abstract][Full Text] [Related]
25. Ligand binding and kinetics of folate receptor recycling in vivo: impact on receptor-mediated drug delivery.
Paulos CM; Reddy JA; Leamon CP; Turk MJ; Low PS
Mol Pharmacol; 2004 Dec; 66(6):1406-14. PubMed ID: 15371560
[TBL] [Abstract][Full Text] [Related]
26. Design and regioselective synthesis of a new generation of targeted chemotherapeutics. Part 1: EC145, a folic acid conjugate of desacetylvinblastine monohydrazide.
Vlahov IR; Santhapuram HK; Kleindl PJ; Howard SJ; Stanford KM; Leamon CP
Bioorg Med Chem Lett; 2006 Oct; 16(19):5093-6. PubMed ID: 16870437
[TBL] [Abstract][Full Text] [Related]
27. Improvement of meta-tetra(hydroxyphenyl)chlorin-like photosensitizer selectivity with folate-based targeted delivery. synthesis and in vivo delivery studies.
Gravier J; Schneider R; Frochot C; Bastogne T; Schmitt F; Didelon J; Guillemin F; Barberi-Heyob M
J Med Chem; 2008 Jul; 51(13):3867-77. PubMed ID: 18553957
[TBL] [Abstract][Full Text] [Related]
28. Folate-linked lipid-based nanoparticles for synthetic siRNA delivery in KB tumor xenografts.
Yoshizawa T; Hattori Y; Hakoshima M; Koga K; Maitani Y
Eur J Pharm Biopharm; 2008 Nov; 70(3):718-25. PubMed ID: 18647651
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and in vitro/in vivo evaluation of novel 99mTc(CO)3-folates.
Müller C; Schubiger PA; Schibli R
Bioconjug Chem; 2006; 17(3):797-806. PubMed ID: 16704220
[TBL] [Abstract][Full Text] [Related]
30. Carbohydrate-based synthetic approach to control toxicity profiles of folate-drug conjugates.
Vlahov IR; Santhapuram HK; You F; Wang Y; Kleindl PJ; Hahn SJ; Vaughn JF; Reno DS; Leamon CP
J Org Chem; 2010 Jun; 75(11):3685-91. PubMed ID: 20423159
[TBL] [Abstract][Full Text] [Related]
31. Folate-targeted drug strategies for the treatment of cancer.
Leamon CP
Curr Opin Investig Drugs; 2008 Dec; 9(12):1277-86. PubMed ID: 19037834
[TBL] [Abstract][Full Text] [Related]
32. Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases.
Low PS; Henne WA; Doorneweerd DD
Acc Chem Res; 2008 Jan; 41(1):120-9. PubMed ID: 17655275
[TBL] [Abstract][Full Text] [Related]
33. Enhancing the therapeutic range of a targeted small-molecule tubulysin conjugate for folate receptor-based cancer therapy.
Leamon CP; Reddy JA; Vlahov IR; Dorton R; Bloomfield A; Vetzel M; Klein PJ; Westrick E; Xu LC; Wang Y
Cancer Chemother Pharmacol; 2017 Jun; 79(6):1151-1160. PubMed ID: 28451831
[TBL] [Abstract][Full Text] [Related]
34. Folate-targeted dinitrophenyl hapten immunotherapy: effect of linker chemistry on antitumor activity and allergic potential.
Lu Y; You F; Vlahov I; Westrick E; Fan M; Low PS; Leamon CP
Mol Pharm; 2007; 4(5):695-706. PubMed ID: 17784727
[TBL] [Abstract][Full Text] [Related]
35. Targeting the folate receptor (FR): imaging and cytotoxicity of ReI conjugates in FR-overexpressing cancer cells.
Viola-Villegas N; Rabideau AE; Cesnavicious J; Zubieta J; Doyle RP
ChemMedChem; 2008 Sep; 3(9):1387-94. PubMed ID: 18651631
[TBL] [Abstract][Full Text] [Related]
36. Reducing undesirable hepatic clearance of a tumor-targeted vinca alkaloid via novel saccharopeptidic modifications.
Leamon CP; Reddy JA; Klein PJ; Vlahov IR; Dorton R; Bloomfield A; Nelson M; Westrick E; Parker N; Bruna K; Vetzel M; Gehrke M; Nicoson JS; Messmann RA; LoRusso PM; Sausville EA
J Pharmacol Exp Ther; 2011 Feb; 336(2):336-43. PubMed ID: 20978169
[TBL] [Abstract][Full Text] [Related]
37. Folate and folate-PEG-PAMAM dendrimers: synthesis, characterization, and targeted anticancer drug delivery potential in tumor bearing mice.
Singh P; Gupta U; Asthana A; Jain NK
Bioconjug Chem; 2008 Nov; 19(11):2239-52. PubMed ID: 18950215
[TBL] [Abstract][Full Text] [Related]
38. Tumour-selective drug delivery via folate receptor-targeted liposomes.
Pan X; Lee RJ
Expert Opin Drug Deliv; 2004 Nov; 1(1):7-17. PubMed ID: 16296717
[TBL] [Abstract][Full Text] [Related]
39. The folate receptor: what does it promise in tissue-targeted therapeutics?
Salazar MD; Ratnam M
Cancer Metastasis Rev; 2007 Mar; 26(1):141-52. PubMed ID: 17333345
[TBL] [Abstract][Full Text] [Related]
40. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
